Despite being an expensive treatment with the possibility of resistance due to the reduced expression or loss of N-linked glycosylation sites in V5 of gp120, ibalizumab remains highly significant for MDR patients [ 37 ].
← all excerpts
Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.
1
—
—